German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery specialist Twist Bioscience (NASDAQ: TWST) to develop antibodies targeting undisclosed disease areas. This collaboration is set to enhance Bayer’s capabilities in antibody discovery and development.
Financial Terms of the Collaboration
Under the terms of the agreement, Bayer will provide an upfront fee and is eligible for up to USD 188 million in milestone payments, along with royalties from successful programs. This financial structure underscores Bayer’s commitment to advancing innovative therapeutic solutions through strategic partnerships.
Leveraging Advanced Technologies
The collaboration will utilize Twist Bioscience’s cutting-edge synthetic DNA libraries and expertise in antibody engineering. By harnessing these advanced discovery and optimization methods, the partnership aims to accelerate the development of effective antibodies, addressing unmet medical needs across various disease areas.-Fineline Info & Tech
